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Introduction
The federal regulation of dietary supplements has traditionally been one of the most controversial issues in food and drug law. With the enactment of the Dietary Supplement Health and Education Act in 1994, the controversy within and among the FDA, Congress, the courts, and the dietary supplement industry has grown. Interestingly, the history of the federal regulation of dietary supplements has seemed to repeat itself: the FDA will tighten its regulatory stance, Congress will enact a statute to reverse the FDA's position, and the FDA will again tighten its regulatory stance. The federal courts have often intervened to settle disputes. In addition to various units of government, the dietary supplement industry is always an important gure in the regulatory battle.
2The tension between those who favor greater
regulation and those who oppose it stems from a
concern about consumer safety poised against a
concern about consumer choice. The FDA and
other public health organizations have expressed
and continue to express safety concerns about the
increased availability of dietary supplements and
the decreased ability of the government to regu-
late them after the enactment of the DSHEA.
Other groups, especially Congress and the di-
etary supplement industry, regard the DSHEA
as a long overdue bastion of consumer choice and
health freedom. This controversy has made the
federal regulation of dietary supplements a hot
topic for academics and practitioners. The pur-
pose of this paper is not to endorse a particular
view on the proper course for regulation. Rather,
this paper is designed to inform the reader of
the various points of view at play in the regu-
latory arena and how those viewpoints translate
into policy.
Because this topic is so controversial, the information available to the re-
searcher is vast. This paper seeks to provide the researcher with a general
overview of the past, present, and future of the federal regulation of dietary
supplements. Part I of the paper briey describes the regulation of dietary sup-
plements between the enactment of the Food, Drug, and Cosmetic Act in 1938
and the enactment of the DSHEA in 1994. During the early stages of regulation,
3the FDA was focused on classifying dietary supplements in order to gain the
maximum amount of authority to regulate them. Predictably, Congress and the
courts responded to further dene the proper contours of federal regulation of
dietary supplements.
Part II of this paper explores the legislative history of the enactment of the
DSHEA. Specically, it details the relevant congressional hearings, reports and
amendments to the bill that would eventually become the DSHEA. Part III of
this paper explores each of the major provisions of the DSHEA.
The next sections of the paper focus on the post-DSHEA dietary supplement
regulatory developments. Part IV addresses the regulation of dietary supple-
ment health and structure/function claims. Part V examines the aftermath of
the DSHEA's broadening of the denition of \dietary supplement." Part VI
of the paper details the safety and burden of proof issues established by the
DSHEA, and Part VII describes the specic regulatory developments of the
DSHEA's labeling and third party literature provisions. As Parts IV-VII will
demonstrate, the post-DSHEA regulatory arena has been marked by attempts
on the part of the FDA to tighten its regulatory hold. Much like pre-1994 di-
etary supplement regulation, the courts have recently stepped in to quash the
eorts of the FDA. Currently, the FDA is developing new regulations to conform
to the mandates issued by the federal courts.
Part VIII of the paper looks to the future of the federal regulation of dietary
supplements by examining recent bills proposed in Congress. Without a doubt,
if the future of the federal regulation of dietary supplements mirrors its past, it,
4too, will be marked by power struggles and controversy. Congress, the courts,
the FDA, industry and consumers will all have dierent opinions as to the best
course for dietary supplement regulation. This tension will only grow with the
ever-increasing availability of vitamins, minerals, and herbal dietary supple-
ments.
5Part I { Pre-1994 Federal Regulation of Dietary Supplements
The proper method of regulation of dietary supplements posed a unique and
dicult challenge for the Food and Drug Administration (FDA) from the very
beginning. The early period of regulation was marked by a set of attempts by
the FDA to classify the dietary supplements in order to gain regulatory author-
ity over them. FDA's rst attempts were to classify dietary supplements as
drugs, followed by a later attempt to classify them as food additives. With each
classication eort, the FDA was trying to gain some pre-market regulatory
power over dietary supplements in order to protect consumers from the increas-
ing amount of dietary supplements on the markets, especially those making
dubious health claims. With each attempt to regulate, the FDA was met by re-
sistance from both Congress and the dietary supplement industry. This section
addresses the early phase of the regulation of dietary supplements and explores
the Nutrition Labeling Education Act of 1990, the Dietary Supplement Act of
1992, and other relevant legislative enactments, as well as the FDA's earliest
regulatory stance toward dietary supplements.
A. Early Regulation of Dietary Supplements as Drugs
Until the Federal Food, Drug, and Cosmetic Act (FDCA) was passed in
1938, dietary supplements were not an issue for federal regulation.1 With the
1The Pure Food and Drug Act of 1906 did not address the regulation of dietary supplements
at all. See Pub. L. No. 59-384, 34 Stat. 768 (1906), 21 U.S.C. xx 1-15 (1934) (repealed by 21
U.S.C. x 329(a) (1938)).
6passage of the FDCA,2 however, the FDA was alerted to the existence of foods
\for special dietary use" as well as the \vitamin, mineral, and other dietary
properties" of those foods.3 The FDA then began its long struggle to classify
dietary supplements as either a food or a drug under the Act. The strategy em-
ployed by the FDA shortly after the passage of the FDCA was to place dietary
supplements within the \drug" provisions of the FDCA because of the health
claims made on the labels and in literature. The strategy quickly became a
subject for scrutiny and Supreme Court review.4
The Supreme Court construed the precise meaning of the term \label" for regu-
latory purposes in a set of cases in 1948. In Kordel v. United States, the Court
held that the term \labeling" is not restricted to \labels that are on or in the
article or package that is transported."5 Such things as accompanying booklets
or literature could also be considered labeling as long as the labeling and the
accompanying booklets or literature were \parts of an integrated distribution
program."6 In United States v. Urbuteit, the Supreme Court further explained
that the formal label and supplementary materials do not have to be attached
or mailed simultaneously if the two transactions are integrated.7 Kordel and
Urbuteit opened the door for the FDA to challenge dietary supplements based
on their labeling and supplementary labeling claims. However, this authority
was tempered in United States v... \Sterling Vinegar and Honey...," in which
2Pub. L. No. 75-717, 52 Stat. 1040 (1938), as amended 21 U.S.C. xx 301 et seq.
321 U.S.C. 343(j).
4Bass, I. Scott and Anthony L. Young. Dietary Supplement Health and Education Act: A Legislative History and Analysis.
The Food and Drug Law Institute, 1996, p. 9.
5335 U.S. 345, 349 (1948).
6Id. at 350.
7335 U.S. 355, 353 (1948).
7the Second Circuit held that \labeling does not include every writing which
bears some relation to the product."8For the next three decades after Kordel
and Urbuteit, the proper use of supplementary materials as labeling under the
FDCA became one of many highly controversial issues between the FDA and
the dietary supplement industry.
In addition to regulating dietary supplements based on labeling, the FDA also
initiated an attack on the substantive potency of dietary supplements following
the enactment of the FDCA. After at least a decade of debate about the scope
of the regulation of vitamins, the FDA issued nal regulations in 1973 stating
that vitamins and minerals with greater than 150% of the Recommended Daily
Allowance potency must be classied as \drugs."9 Congress responded to the
FDA's increased regulatory power in 1976 with the enactment of The Prox-
mire Act, named for its sponsor Senator William Proxmire, which amended the
FDCA.10 The Proxmire Act (1) took away FDA's authority to set maximum
limits on the potency of any vitamin or mineral, (2) revoked FDA's authority to
regulate vitamin and mineral potency for purposes of classifying the vitamin or
mineral as a drug, (3) expanded the terms under which the vitamins and min-
erals could be marketed, and (4) permitted certain special dietary needs claims
that would not be considered drug claims.11 Essentially, after the enactment
of the Proxmire Act, the FDA could no longer declare high doses of dietary
8338 F.2d 157, 158-159 (2d Cir. 1964).
938 Fed. Reg. 20,730, 20,732 (Aug. 2, 1973). Exceptions to this nal regulation were
Vitamin A (classied as a drug in doses exceeding 200% of the RDA) and Vitamin D (classied
as a drug in doses exceeding 100% of the RDA).
10Pub. L. No. 94-278, 90 Stat. 401 (1976), 21 U.S.C. x 350.
1121 U.S.C. xx 350(a)(1-2); Bass at 12-13.
8supplements to be drugs in order to regulate them.12
B. Early Regulation of Dietary Supplements as Food Ad-
ditives
From then on, the FDA took the position that a dietary supplement ingredient
could be characterized as a \food additive" because it was added to a capsule or
tablet to create the dietary supplement. Therefore, the additive could be sub-
ject to the pre-market approval process (assuming it is not generally recognized
as safe or subject to a food additive regulation) and subsequently be deemed
adulterated as or as containing \unsafe food additives" under the FDCA.13The
manufacturers asserted that dietary supplement ingredients were generally rec-
ognized as safe. They also believed that the FDA's interpretation of the FDCA
placed the burden of proving the safety of the dietary supplements (\foods") on
them instead of on the FDA.14
In 1993, the First and Seventh Circuits responded and struck down the FDA's
interpretation as to single-ingredient dietary supplements15 but not multiple in-
gredient dietary supplements.16 In United States v. Two Plastic Drums ...Black Currant Oil,17
the most often cited of the two cases, the Seventh Circuit Court of Appeals
12Consequently, \if such products did not bear unauthorized `drug claims,' then a new drug
or drug misbranding theory also could not be applied." Bass at 13.
1321 U.S.C. x 348.
14Bass at 14.
15See United States v. 29 Cartons of ...An Article of Food, Etc., 987 F.2d 33 (1st. Cir.
1993); United States v. Two Plastic Drums ...Black Currant Oil, 984 F.2d 814 (7th Cir.
1993).
16See United States v. 42/194 kg. Drums of Pure Vegetable Oil, 961 F.2d 808 (9th Cir.),
cert. denied, 506 U.S. 940 (1992) (supplement containing both Evening Primrose Oil and
Vitamin E held to be an unapproved food additive).
17Black Current Oil, 984 F.2d 814 (7th Cir. 1993).
9struck down an FDA seizure and condemnation of black current oil. The FDA,
relying on its food additive stance for dietary supplements, claimed that the
glycerin and gelatin capsules were food and thus the oil in the capsules was
an unsafe food additive. The Court, however, rejected the FDA's argument,
holding that black currant oil is a dietary supplement itself, not a component of
dietary supplement and, thus, is a food and not a food additive.18 The Court
reasoned that a substance that is simply a component of food does not satisfy
the food additive standard. Instead, a substance must have the eect of alter-
ing a food's characteristics to be considered a food additive.19 Clearly upset
with the FDA's interpretation, the Court stated that \the FDA's food additive
denition is so broad, however, that it would... classify every component of
food|even single active ingredients|as food additives. Thus, it would seem,
even the addition of water to food would make the food a food additive. The
only justication for this Alice-in-Wonderland approach is to allow the FDA to
make an end-run around the statutory scheme and shift to the processors the
burden of proving the safety of a substance in all circumstances. To be sure,
the paramount objective of the Act is to protect the public health."20 Con-
sequently, this decision and other decisions echoing its sentiment signicantly
decreased the FDA's ability to regulate dietary supplements as food additives.
C. Early Regulation of Dietary Supplement Health Claims
18Id. at 817.
19Id.
20Id. at 819.
10The need for some further type of regulation of dietary supplements was ob-
viated in 1989 when there was an outbreak of at least 1500 cases of eosinophilia
myalgia syndrome caused by the use of substances containing L-tryptophan,
an amino acid.21 L-tryptophan purported to improve one's health. Its use,
however, resulted in thirty-eight deaths.22 The FDA's increased attempts to
regulate dietary supplements as either drugs or food additives were sparked
in part by this outbreak and also by a general concern about unsubstantiated
health claims. The FDA began to consider the availability of some health claims
for foods, but it pointed out that health claims for dietary supplements were
unlikely to be approved.23 Particularly, the FDA believed there was no scientic
basis for health claims for dietary supplements.
To stem the rise of unsubstantiated health claims, Congress enacted the Nu-
trition Labeling and Education Act of 1990 (NLEA).24 Basically, the NLEA
allowed the FDA to screen health claims for scientic soundness.25 The NLEA
authorized the use of health claims that characterized the \relationship of any
nutrient... to a disease or health-related condition" on food labels, but the claim
had to be deemed reliable.26 To determine what claims are reliable, Congress
directed the FDA to promulgate regulations for both conventional foods and di-
etary supplements. For conventional food products, Congress directed the FDA
21Khatcheressian, Laura A.W. \Regulation of Dietary Supplements: Five Years of DSHEA."
54 Food and Drug Law Journal 623, 625 (1999).
22Id. at 625.
23See 52 Fed. Reg. 28,843 (Aug. 4, 1987); 55 Fed. Reg. 5176 (Feb. 13, 1990).
24Pub. L. No. 101-535, 104 Stat. 2353 (1990), 21 U.S.C. xx 301 note, 321, 337, 343, 343
notes, 343-1, 343-1 note, 345, 371.
25Vladeck, David C. \Devaluing Truth: Unveried Health Claims in the Aftermath of
Pearson v. Shalala." 54 Food and Drug L.J. 535 (1999).
2621 U.S.C. x 343(r)(1)(B).
11to use a standard of \signicant scientic agreement" based on the totality of
available scientic evidence among qualied experts to evaluate such claims.27
Congress delegated the task of establishing dietary supplement standards to the
FDA.28 It is evident from the statements of the House Floor Managers of both
parties of Congress that Congress intended that the standards of reliability for
dietary supplement labelings be at least as strong as the standards for food
labeling under the NLEA.29
Therefore, pursuant to the NLEA, the FDA was allowed to consider dierent
approval procedures and scientic evaluation standards for dietary supplement
health claims and conventional food health claims.30 FDA was given author-
ity to bring enforcement actions when supplements were marketed with claims
that were not approved by the FDA.31 The NLEA further instructed the FDA
to evaluate the following potential health claims for dietary supplements and
other conventional foods:

calcium and osteoporosis;

2721 U.S.C. x 343(r)(3)(B)(i).
28Id. x 343(r)(5)(D).
29Cong. Rec. H12953 (Oct. 26, 1990) (dietary supplements \covered by this provision
should be subject to at least as strong a standard as is applicable to other foods").
30Id. x 343(r)(5)(D).
3121 U.S.C. x 343(r)(1)(B).
12dietary ber and cancer;

lipids and cardiovascular disease;

lipids and cancer;

sodium and hypertension;

dietary ber and cardiovascular disease;

folic acid and neutral tube defects;

antioxidant vitamins and cancer;

zinc and immune function in the elderly; and
13
omege-3 fatty acids and heart disease.32
In late 1991, the FDA proposed implementing regulations that opted to use
the \signicant scientic agreement" standard for dietary supplements, as well
as for foods.33 In the absence of \signicant scientic agreement," the claim is
to be considered \unreliable." Using this standard, FDA rejected nearly all of
the above health claims for dietary supplements.34
Predictably, the FDA faced much resistance from industry because of its re-
luctance to approve health claims on dietary supplements. By the early 1990s,
the dietary supplement industry in the United States had grown to a several
billion-dollar business.35 The industry was angry not only about the FDA's food
additive enforcement theory and its decision not approve most health claims, but
also about the FDA's stance regarding \structure/function" claims.36 Speci-
cally, the FDCA dened a drug as \articles (other than food) intended to aect
the structure or any function of man or other animals."37The dietary supplement
industry interpreted this provision, specically the \other than food" statement,
to provide a basis for structure/function claims for foods. The FDA, however,
maintained the position that \food" did not include dietary supplements other
3221 U.S.C. x 343 note 7.
33S.Rep.No. 103-410, 103d Cong., 2d Sess., October 8, 1994 at 15.
34Id. The health claim that calcium may prevent osteoporosis was proposed for a limited
population of white and Asian women. 58 Fed. Reg. 2665 (Jan. 6, 1993). A folic acid/neutral
tube defect health claim for pregnant women or women of child bearing years was added later.
59 Fed. Reg. 433 (Jan. 4, 1994).
35Bass at 15.
36Id.
3721 U.S.C. 321(g) (1)(C) (emphasis added).
14than vitamins and minerals with recognized nutritional value.38 Therefore, un-
der the FDA's view, any structure/function claim made by a dietary supplement
(other than a vitamin or mineral with recognized nutritional value) was an un-
approved drug claim. The FDA's position, despite industry protest, was ratied
in the courts.39 The battle between the industry and FDA set the stage for the
enactment of the Health Freedom Act of 1992 and the Dietary Supplement Act
of 1992.
D. Congressional Reaction
The Health Freedom Act of 199240 attempted to change the landscape of the
regulation of dietary supplements in the following ways: (1) it broadened the
denition of \dietary supplement to include herbs and other nutritional sub-
stances, (2) it recognized that prior eorts to regulate dietary supplements as
either a food or drug were inappropriate, (3) it precluded dietary supplements
from being regulated as drugs upon a proper showing, and (4) it exempted
dietary supplement health claims from pre-market approval. A large public re-
lations and lobbying battle ensued in Congress, and ultimately, it became clear
to the bill's sponsor, Senator Orrin Hatch, that the likelihood of passage was
low.41
Therefore, Senator Hatch proposed two measures to address the NLEA's di-
etary supplement provisions and the FDA's stance regarding the regulation of
38Bass at 15.
39See, e.g., Nutrilab v. Schweiker, 713 F.2d 335 (7th Cir. 1983).
40S. 2385. 102d Cong., 2d Sess. (1992).
41Bass at 20.
15dietary supplements.42 First, Senator Hatch proposed a one-year moratorium
on implementing the dietary supplement provisions of the NLEA, noting that:
We [the Congress] did not intend for the FDA to treat dietary supplements
like drugs, which is the way they are treating them, or intend to treat them.
Instead... the FDA decided to put herbs in the same regulatory category as
tetracycline, and vitamin A in the same category as insulin. People are outraged
about this, and I am too.43
The amendment passed the Senate but did not proceed any further. How-
ever, the second measure to change the regulatory scheme was already being
proposed. The Dietary Supplement Act (DSA) was added to the Prescription
Drug User Fee Act of 199244 and provided a one-year moratorium on dietary
supplement health claims, nutrient content claims, and labeling. The FDA was
required to issue proposed rules for the claims involved in the moratorium by
June 15, 1993. The FDA was instructed to issue its nal rules by December 31,
1993.45
Additionally, the DSA required that three reports be issued. The rst report
involved the Health and Human Services Department detailing the enforcement
policies and practices of the FDA to determine whether there was discrimina-
tion against dietary supplements. The report was issued in May of 1993 and
concluded that no discrimination had occurred.46 A second similar report by
the Comptroller General issued no conclusion.47
The third report was a comparison of dietary supplement regulation and mar-
42Id. at 20-21.
43Cong. Rec. S13,974-75 (Sept. 18, 1992).
44Pub. L. No. 102-571; 106 Stat. 4491 (1992).
45Bass at 21.
46Id.
47Id.
16keting in the United States and foreign countries. The report was issued by the
Oce of Technology Assessment and was mainly a historical study. Thus, it
did not directly address the controversies within the regulation of dietary sup-
plements.48
The DSA, however, set the stage for an expanded debate on the federal reg-
ulation of dietary supplements. This debate, marked by power struggles and
tension between the Congress, industry and the FDA, would eventually lead to
the enactment of the Dietary Supplement Health and Education Act during the
next legislative session.
48Id.
17Part II { The Legislative History of the Dietary Supplement Health and Education Act
The legislative history for the Dietary Supplement Health
and Education Act is a very interesting and thorough look
at the competing views and compromises that carved out
the nal bill. The battle between the FDA, regulated in-
dustry and Congress carried over from the pre-1992 regu-
latory context to the debate about the passage of the bill
that would eventually become the DSHEA.
The documents in the unocial legislative history consist of numerous oor
excerpts, four principal hearings, and one extremely thorough Senate Report.
The bill that was eventually passed was introduced in the Senate, and a com-
panion bill was introduced in the House. This section will explore the purpose
of the bills introduced in the House and Senate and will compare and contrast
the two bills. Additionally, it will examine the hearings that accompanied the
bills and the suggestions to amend them. Finally, this section will examine
the Senate Report accompanying the passage of the Senate bill, focusing in on
the examples of the health advantages of dietary supplement use put forth by
Congress to spark the passage of the bill.
A. Purpose of the Bills
Less than one year after the Dietary Supplement Act, Senator Orrin Hatch
introduced S. 78449 on April 7, 1983. H.R. 1709,50 the companion bill to S. 784,
49S. 784, 103d Cong., 1st Sess. x 3 (1993).
50H.R. 1709, 103d Cong., 1st Sess. x 2 (1993).
18was introduced in the House on the same day by Congressman Bill Richardson
of New Mexico. The purpose of both bills was to balance the need for the quality
and safety of dietary supplements against the consumer's desire to have access
to health information about dietary supplements.
In Senator Hatch's Statement on Introduction of S. 784, he stated:
This legislation empowers consumers to make choices about their personal
preventative health care regiments based on accurate health benets related
to particular dietary supplements. These claims will be based on either an
FDA-approved claim or on a claim that accurately reects the current state of
scientic evidence concerning a dietary supplement's health benets. The FDA
will continue to have the responsibility and power to ban a supplement found
to present a substantial risk to consumers. This legislation provides consumers
with needed information about dietary supplements and provides the FDA and
the dietary supplement industry with clear direction for a much needed over-
haul of the current regulatory approach. This legislation provides for more and
accurate information on labels than is currently found on dietary supplement
labeling and contains additional consumer safety provisions.51
It is clear from the opening remarks of Senator Hatch that the bill that would
eventually become the Dietary Supplement Health and Education Act (DSHEA)
was designed from its inception to change the face of federal regulation of dietary
supplements. The Statement of Rep. Richardson on Introduction of H.R. 1709
echoes Senator Hatch's sentiment:
Dietary supplements still lack an appropriate regulatory framework that will
allow appropriate health claims. We need a standard that will allow truthful
nonmisleading health claims for dietary supplements based upon a reasonable
level of scientic evidence. My legislation will accomplish this objective by al-
lowing health claims to be made for dietary supplements if: First, the FDA has
approved a claim for the same nutrient contained in a food. For example, if
the FDA approves claims for beta-carotene in cruciferous vegetables like broc-
coli, a beta carotene supplement may make the same claim; or second, accurate
statements that consider the totality of scientic evidence concerning a nutri-
ent/disease relationship. Manufacturers are required to provide information in
advance to the FDA about any claims made about the product. Supplements
51Cong. Rec., S4577 (April 7, 1993). (emphasis added).
19will also be permitted to describe truthful physiological benets that are not
health claims, as in the statement: \Calcium builds strong bones."
This legislation seeks to both protect consumers' rights to obtain dietary
supplements and herbs; and assures them that they will be safe, of high quality,
and that the information about them will be truthful and not misleading. Amer-
icans want greater freedom, participation, and expanded options for themselves
in health care, not less.52
B. Comparison and Contrast of the Proposed House Version and Proposed Senate Version of the Bills
While the House and Senate versions of the bills were similar in their purposes,
the two bills were dierent in some respects as well. The denitions of dietary
supplement in both versions were essentially the same. Each broadened the
\special dietary use" denition by expanding the scope from vitamins and min-
erals to include herbs, amino acids, and others.53 H.R. 1709 also broadened the
admissible form of dietary supplements, permitting them to take essentially any
form, while the Senate version restricted the dietary supplement forms to the
traditional dietary supplement forms. Additionally, each version also excluded
dietary ingredients and/or ingredients to be used in dietary supplements from
the statutory denition of "food additive."
A somewhat important dierence between the House and Senate versions con-
cerned the existence of the broad exclusion of dietary supplements from the
drug category. The Senate version contained this exclusion, which expanded
the Health Freedom Act's prohibition on potency as a basis for categorizing a
vitamin or mineral as a drug for regulatory purposes.54 x 3(b) of S. 784 stated
explicitly that the term \drug" did not include a dietary supplement or dietary
supplement ingredient. H.R. 1709 did not contain a parallel exclusion.
52Cong. Rec., E920 (April 7, 1993).
53Bass at 24.
54Id.
20Each bill attempted to respond to public criticism about safety issues. The
elimination of FDA authority to regulate based on the food additive theory in
combination with proposed restrictions on regulations derived from the Health
Freedom Act left the FDA virtually powerless to regulate the safety of dietary
supplements. In response to these concerns, the bills provided the FDA with
explicit rulemaking authority in the case of a \substantial or unreasonable risk
of illness or injury" posed by a dietary supplement or dietary supplement in-
gredient.55 Additionally, each bill proposed that a manufacturer or supplier of
a dietary supplement be required to substantiate safety through (1) evidence
of a history of safe use and the absence of information that brings safety into
question, (2) by scientic studies conducted with generally recognized scientic
procedures or principles, or (3) by any other appropriate means.56
The nal safety issues addressed in both versions of the bill were manufacturing-
induced safety or contamination issues.57 H.R. 1709 required raw material man-
ufacturers to notify the FDA if they made signicant changes in their manufac-
turing process that had been shown to present adverse safety consequences.58
S. 784 had a milder requirement { it called for a report on the subject from the
\Director of the Oce of Dietary Supplements."59
55S. 784, supra note 49, x 4; H.R. 1709, supra note 50, x 3(a).
56Any dietary supplement that had an established RDA or an estimated safe dietary intake
level was excluded. S. 784, supra note 49, x 4; H.R. 1709, supra note 50, x 3.
57This safety issue was brought to the attention of Congress in part because of the L-
tryptophan outbreak in 1989. See \Regulation of Dietary Supplements," Hearing Before
the Subcommittee on Health and the Environment of the House Committee on Energy and
Commerce, ( July 29, 1993), p. 65. (statements of Rep. Bill Richardson and David A Kessler,
FDA Commissioner, expressing concern about the proposed legislation with respect to safety
issues).
58H.R. 1709, supra note 50, x 3(a).
59S. 784, supra note 49, x 5.
21There were no substantive dierences between the bills with respect to the
issues of permissible and non-permissible health claims. H.R. 1709 and S. 784
both removed the \signicant scientic agreement" standard used previously by
the FDA to approve health claims and replaced it with a more lenient standard.
Under each version, the FDA was authorized to approve dietary supplement
health claims if (1) the FDA previously authorized the claim for a conventional
food containing the particular dietary supplement ingredient or (2) the health
claim \accurately represent[ed] the current state of scientic evidence."60 The
second prong of the proposed standard was designed to allow the FDA to ap-
prove health claims when they were based on something less than scientic
consensus. Additionally, it would have permitted precatory language in health
claims, e.g., \studies may indicate a relationship between the consumption of
this nutrient and the prevention of chronic heart disease."61 This portion of
the proposed bills represented a clear break from past FDA procedures and
manifested Congress's intent to more freely provide consumers with dietary
supplement health-related information.
Additionally, the bills contained an exemption for \truthful and non-misleading"
information about the about how the supplement aects the \physiological pro-
cesses of the body" or how it prevents or repairs damage caused by diet or other
environmental factors.62 These claims would therefore not be subject to the
60S. 784, supra note 49, x 7; H.R. 1709, supra note 50, x 4.
61Bass at 25.
62S. 784, supra note 49, x 7; H.R. 1709, supra note 50, x 4.
22NLEA health claims approval process.
The bills also contained the following provisions:
(1)
In response to the dietary supplement industry's belief that FDA's warning
letters were being overutilized as a way to obtain compliance, both bills deemed
warning letters to be a nal adjudication for purposes of attaining judicial re-
view.63
(2)
Both bills contained a provision that protected all forms of dietary supple-
ments from any FDA compositional or potency limits.
(3)
Each bill contained new misbranding and labeling standards. These stan-
dards were designed primarily to ensure label uniformity and potency.
(4)
Both bills created an Oce of Dietary Supplements within the National In-
stitutes of Health to provide guidance on dietary supplement use based on its
own research and analysis. This new oce would not be a part of the FDA.
63The FDA took the position that an issuance of a warning letter was not a nal agency
action and therefore not reviewable in federal court.
23C.
The Hearings in Congress
To understand the hearings process, it is necessary to discuss briey the
activities going on in the FDA at the time. Within the FDA, Commissioner
Kessler appointed a Task Force on Dietary Supplements to issue a report that
addressed the many inquiries the FDA received from the public regarding the
regulation of dietary supplements.64 The report was issued in June of 1993.
Much of the report was used as background information for an advance notice
of proposed rulemaking on dietary supplements that the FDA was about to
issue.65 The advance notice of proposed rulemaking angered many people in
Congress and certainly the dietary supplement industry because it took the
position that dietary supplements should be regulated as drugs. This occurred
immediately before the hearings process began in Congress.
There were several committee hearings in Congress, all of which brought out
various interests and points of view. The following is a list of relevant hearings
that occurred in various subcommittees in Congress.
(1) \Food and Drug Administration's Regulation of Dietary Supplements,"
Hearing Before the Subcommittee on Human Resources and Intergovernmental
Relations, Committee on Governmental Relations, House of Representatives,
July 20, 1993.
64Bass at 26.
6558 Fed. Reg. 33,690, 33,691 (June 18, 1993).
24This early hearing is focused primarily on the dietary supplement issues un-
der the NLEA. Specically, this hearing contains testimony from food science
and nutrition professors endorsing FDA's health supplement labeling require-
ments to protect consumers.
(2) \Regulation of Dietary Supplements," Hearing Before the Subcommittee
on Health and the Environment, Committee on Energy and Commerce, House
of Representatives, July 29, 1993.
This was one of the major hearings on the issue presided over by Congress-
man Waxman. Congressman Waxman pointed out the fact that the FDA was
in a very dicult situation because it was receiving a good deal of mixed signals
from Congress and the public. He noted that the goal of the legislative process
should be to \guarantee the availability of safe dietary supplements as long as
they make no unproven claims."66
David Kessler (FDA Commissioner) and Samuel Broder (Director, National
Cancer Institute) (as well as others) testied and expressed concern about the
proposed legislation and the possibility of future unsubstantiated health claims.
Specically, Commissioner Kessler noted the hundreds of dietary supplements
that claim to cure or treat various serious illnesses such as cancer. Moreover,
he noted safety concerns about the dietary supplements, since many adverse
reactions could go unrecognized and unreported. Finally, he argued that the
66\Regulation of Dietary Supplements," Hearing Before the Subcommittee on Health and
the Environment, Committee on Energy and Commerce, House of Representatives, July 29,
1993, p. 1.
25Senate bill would have the practical aect of putting the burden of proof for
safety on the FDA, rather than on industry. Additionally, various representa-
tives from diering groups also testied to the need for decreased regulation of
dietary supplements.
(3) \Agriculture, Rural Development, Food and Drug Administration, and
Related Agencies Appropriations for 1994. Dietary Supplements," Hearing Be-
fore the Subcommittee on Agriculture, Rural Development, FDA, and Related
Agencies Appropriations, Committee on Appropriations, House of Representa-
tives, October 18, 1993.
This hearing examined the FDA's interpretation of the NLEA and the bills
(S. 784 and H.R. 1709) to restrict the FDA's power to regulate dietary supple-
ments. Sen. Hatch and others testied to the need to restrict FDA regulation
in this area. Victims of complications regarding the use of dietary supplements
and representatives from various interest groups testied to the contrary need
for the increased FDA regulation of dietary supplements. Dr. David Kessler
testied as to the necessity for regulation and related complications regarding
regulation.
(4) \Legislative Issues Relating to the Regulation of Dietary Supplements,"
Hearing Before the Committee on Labor and Human Resources, U.S. Senate,
October 21, 1993.
Dr. David Kessler testied to issues relating to unsubstantiated health
26claims and the safety of various dietary supplements. He tried to diuse rumors
that the FDA was planning to remove dietary supplements from the shelves,
stating that the FDA had no problem with industry selling dietary supplements
that were indeed safe.67 The FDA, therefore, focused more on the health claims
of dietary supplements than on the safety of their ingredients in this particular
hearing.68
Senator Hatch, however, stated that he recognized that the Senate bill may not
adequately address safety concerns, and acknowledged that the language of the
bill may need to be more clearly written to prevent false and misleading health
claims.69 Senator Hatch also criticized the FDA Report, noting that he believed
the much of the information in the report was inaccurate or out of date.
Timothy Dyk, an attorney with Jones, Day, Reavis, and Pogue, testied at this
hearing that the proposed regulation of dietary supplements by the FDA could
have First Amendment consequences. Various doctors testied that they had
seen very little in the way of serious side eects from the use of dietary supple-
ments.
Additionally, representatives from the Nutritional Health Alliance and the Cen-
ter for Preventative Medicine testied generally to their concerns about the
FDA regulation of dietary supplements.
The two most important hearings were the House hearing before the Sub-
67\Legislative Issues Relating to the Regulation of Dietary Supplements," Hearing Before
the Committee on Labor and Human Resources, U.S. Senate, October 21, 1993, p. 19.
68Bass at 28.
69\Legislative Issues Relating to the Regulation of Dietary Supplements," Hearing Before
the Committee on Labor and Human Resources, U.S. Senate, October 21, 1993, p. 9.
27committee on Health and the Environment and the Senate hearing before the
Committee on Labor and Human Resources. The tension between the FDA,
Congress, and regulated industry was apparent in the hearings and grew to
its highest point immediately after the hearings. In response, the industry
organized a \National Blackout Day" where retailers draped targeted dietary
supplements in black to show consumers what could be taken o the shelf.70
Partly in response to the growing tension, Congressman Waxman proposed a
compromise amendment to establish a cooling-o period.71 The \Dietary Sup-
plement Access and Claims Moratorium Act of 1993" was designed to ensure
access to dietary supplements and provided a moratorium on dietary supple-
ment claims through June 1994. The access portion of the bill provided that
foods and dietary supplements were adulterated if they contained a dietary in-
gredient or were a dietary supplement that could be injurious to health. This
bill, however, did not make it to a oor vote and was not considered in the
1994 term of Congress. It did, however, inuence the debate in the next term
of Congress.72
D. The Next Term of Congress and the Senate Amendment
At the beginning of the next term of Congress, Senator Hatch introduced an
amended version of S. 784 in order to forge a compromise between the Senate
and the House. The new version contained the following changes:
70Bass at 28.
71H.R. 3650, 103d Cong., 1st Sess. x 2 (1993).
72Bass at 29.
28
FDA was given greater safety authority for emergency situations. The Sec-
retary was given authority to act against dietary supplements that posed a
substantial and imminent public health threat.73

While still not considered a \drug," the denition of dietary supplement was
tightened.74

The amendment makes clear the fact that health claims for dietary sup-
plements will be subject to pre-market approval under the NLEA. Thus, the
portion of the previous version that allowed an unrestricted right to make a
health claim was deleted.75

The amendment allowed dietary supplement manufacturers to make struc-
ture/function claims or statements of nutritional support.76

73Cong.Rec. S11,705, 11,709 (Aug. 13, 1994).
74Id.
75Id. at S11,710.
76Id. at S11,709.
29The amendment allowed for truthful and non-misleading third-party liter-
ature to be distributed to consumers as part of the marketing of dietary sup-
plements, provided the information is balanced, does not promote any specic
brand, and is kept physically separate from the products.77

The amendment included a general good manufacturing process requirement
for manufacturers of dietary supplements.78
E. Passage of the Final Bill
This bill passed the Senate unanimously on August 13, 1994. When the bill
got to the House, Senator Waxman oered an amendment that made further
changes to Senator Hatch's version. The further amended S. 784 passed the
House by unanimous voice vote on October 6, 1994.79
The bill was named the \Dietary Supplement Health and Education Act"
and was signed into law on October 25, 1994. At the signing, President Clinton
noted:
After several years of intense eorts, manufacturers, experts in nutrition, and
legislators, acting in a conscientious alliance with consumers at the grassroots
level, have moved successfully to bring common sense to the treatment of dietary
supplements under regulation and law. More often than not, the government has
been their ally. And the private market has responded to this development with
77Id.
78Id. at S11,710.
79Bass at 30. The nal version of the bill will be discussed in length in Part III of this
paper.
30the manufacture of an increasing variety of safe supplements. But in recent
years, the regulatory scheme designed to promote the interests of consumers
and a healthful supply of good food has been used instead to complicate choices
consumers have made to advance their nutritional and dietary goals. With
perhaps the best intentions, agencies of government charged with protecting
the food supply and the rights of consumers have paradoxically limited the
information to make healthful choices in an area that means a great deal to
over 100 million people.... Simply stated, the legislation amends the [FDCA]
to establish new standards for the regulation of dietary supplements including
vitamins, minerals, and herbal remedies.80
President Clinton's Signing Statement makes clear
that the intent of the DSHEA was to change the
existing regulatory stance toward dietary supple-
ments in a fairly dramatic way. It directly criti-
cizes the FDA's current policy on dietary supple-
ments. After its passage, nearly every provision
of the DSHEA would prove to be controversial.
Within the next few years, many would argue
that the FDA was correct in wanting to keep a
tight reign on the unfettered proliferation of di-
etary supplements and health claims.
F. The Senate Report
The Senate Report issued to accompany S. 784 contains a wealth of
information about the background, purpose and specic provisions
of the DSHEA. Specically, the Senate Report addresses the poten-
tial benets of vitamins and minerals, herbs, amino acids, and other
dietary supplements. In order to understand how the DSHEA was
designed to benet consumers, it is also necessary to briey explore
the purported benets of these various dietary supplements.
Noting that a vast majority of people do not get the full Recommended Daily
Allowance of 10 key vitamins and minerals, the Senate Report81 stated that
80President's Signing Statement, October 25, 1994.
81S.Rep.No. 103-410, 103d Congress, 2d Sess, October 8, 1994.
31dietary supplements are necessary to ensure Americans meet their basic nutri-
tional requirements. In particular, the poor and elderly are especially likely to
have poor vitamin intake. Vitamins and minerals are also necessary to protect
fetal health and to decrease the risk of birth defects. In particular, the Report
notes the example of folic acid (a B vitamin) to prevent neural tube defects such
as spina bida and anencephaly. Additionally, the Report notes that current
research shows that a number of vitamins and minerals can help protect against
a lot of chronic, deadly diseases, such as heart disease, cancer, and osteoporo-
sis.82
The Report focuses on the impact that over-regulation may have on the pre-
vention of life-threatening diseases. In particular, if an individual consumes 10
times the RDA of vitamin E, there is a known potential to reduce the risk of
heart disease. The FDA had recently proposed to limit the amounts of vitamins
that could be sold to the RDA or a small multiple of the RDA. The Report
states that \if such a limit had been in place, people would not have access to
vitamin E in the amounts of 100 IU and more, and we would never have learned
about the potential eect of vitamin E in reducing heart disease risk."83The
Report goes on to list numerous other instances in which high doses of vitamins
provide a signicant health advantage to consumers.
The Report also identies herbs as an important method to enhance di-
ets with substances found in plants and vegetables. The Report takes pains
82S.Rep.No. 103-410 at 5.
83Id. at 6.
32to distinguish herbs from conventional drugs: \Unlike many drugs, the role of
herbal dietary supplements is to enhance the diet by adding safe and natural
plants and their constituents to support and protect bodily functions and pro-
cesses. Containing combinations of numerous naturally occurring plant chemi-
cals, herbs generally act in a wider, more general, less specic way than most
single-ingredient pharmaceutical drugs. Their actions are more `gentle' than
conventional medicines and work usually in more long-term situations."84 The
Report cites various studies, including studies pointing to the eect of garlic on
cholesterol, ginkgo on peripheral circulation, ginseng on endurance and stamina,
and ginger on nausea and stomach distress. Finally, the Report notes that other
modern, industrialized nations such as Canada, England, France, and Germany
have regulatory systems that acknowledge the potential benets of herbs.
The Report states that amino acids may also be useful in improving health in
America. Like the herbal and vitamin examples, the Report cites many studies
showing a correlation between amino acid intake and increased health. For ex-
ample, the Report cites research that reveals that L-Arginine (an amino acid)
increased the body's immune response of white blood cells by over 350 percent.
Additionally, other amino acids have been shown to reduce aliments ranging
from depression to narcolepsy.
The Senate Report also details the history of the FDA's regulatory eorts, not-
ing the FDA's \heavy-handed enforcement agenda against dietary supplements
for over 30 years."85 The Report discusses briey the FDA's attempts to reg-
84Id. at 7. Quoting Weiss, R.F. 1988 \Herbal Medicine." Beaconseld Publishers, England.
85Id at 10.
33ulate dietary supplements as drugs and food additives and notes that both of
these avenues have been unsuccessful. Additionally, the Report notes the many
times courts have struck down FDA policies, discussing specically the Black
Current Oil case.86 The Report noted that the court decisions show that \the
FDA has been distorting the law in its actions to try to prevent the marketing
of safe dietary supplement substances."87
The remainder of the Senate Report discusses the views of the Committee of
Labor and Human Relations on the specic provisions of the DSHEA. When
necessary and to avoid duplication, the Committee's views will be incorporated
into Part III of this paper.
G. The \Ocial" Legislative History
While the Senate Report and the hearings appear to be useful tools, it is in-
teresting to note that they are excluded from the \ocial" legislative history
accompanying the DSHEA. The ocial one-page \Statement of Agreement"
notes that \no other reports or statements [should] be considered as legislative
history for the bill."88 Thus, the formal legislative history gives virtually no in-
sight into Congress' intentions regarding the enactment of the DSHEA. As this
part of the paper has tried to demonstrate, however, the unocial legislative
history contains a good deal of information about what Congress intended the
DSHEA to accomplish.
86See supra note 15.
87S.Rep.No. 103-410 at 10.
881994 U.S.C.C.A.N. x 3523.
34Part III { The Specic Provisions of the Dietary Supplement Health and
Education Act
The DSHEA signicantly altered the way in which the FDA regulated dietary
supplements. First, the DSHEA prohibited the FDA from regulating dietary
supplements as \food additives"89 or generally as drugs. Therefore, the FDA
could no longer require pre-market clearance under the rubric of food additives
or drugs from dietary supplement manufacturers. The DSHEA created a new
category of \dietary supplements" to be regulated in an attempt to clear up
earlier confusion about the regulation of dietary supplements as foods or drugs.
Finally, the DSHEA liberalized the laws governing dietary supplement labeling
and created special oces outside of the FDA designed to research and develop
dietary supplement health issues and policy.
A. The Denition of \Dietary Supplement"
The DSHEA as enacted denes \dietary supplement" as \a product (other than
tobacco) intended to supplement the diet that bears or contains one or more of
the following dietary ingredients:
(A)
a vitamin;
(B)
a mineral;
89Note that only products composed of multiple ingredients were regulated as food additives
before the DSHEA. See supra notes 15 and 16.
35(C)
an herb or other botanical;
(D)
an amino acid;
(E)
a dietary substance for use by man to supplement the diet by increasing the
total dietary intake; or
(F)
a concentrate, metabolite, constituent, extract, or combination of any ingre-
dient described in clause (A), (B), (C), (D), or (E)."90
Section (F) \was intended to capture the widest range of dietary ingredients
and the materials that make up those ingredients."91 Therefore, the new de-
nition of dietary supplements was designed to be broad.
The DSHEA also removed dietary supplements and dietary supplement ingredi-
ents from the denition of food additive.92 This clause was passed in Congress
without argument,93 given that the FDA had largely been prevented from reg-
ulating dietary supplements as food additives before this provision was passed.
9021 U.S.C. x 321()(1)(A-F).
91Bass at 35.
9221 U.S.C. x 321(s).
93Bass at 33.
36Generally under the DSHEA, dietary supplements are not considered \drugs."
However, dietary ingredients rst marketed as new drugs are not included in
the denition of dietary supplements unless the FDA has issued a regulation to
the contrary.94 Ingredients that became new drugs but were rst marketed as
foods could continue to be sold as dietary supplements unless the FDA issued a
regulation to the contrary.95 While dietary supplements are not to be construed
as drugs generally, the FDA was given the power to declare a product to be a
drug if inappropriate claims are made for it.96 The DSHEA states that \except
for purposes of section 201(g), a dietary supplement shall be deemed to be a
food within the meaning of the Act."97 Section 201(g) contains the denition
of a drug and includes \articles intended for use in the diagnosis, cure, miti-
gation, treatment, or prevention of disease in man or other animals."98 It also
includes articles, other than food, intended to aect the structure or function
of the body.99
B. Provisions for New Dietary Ingredients on the Market
Under the DSHEA, a dietary supplement which contains a new dietary ingredi-
ent will be considered adulterated unless one of the following requirements are
met:
9421 U.S.C. x 321()(3)(B).
9521 U.S.C. x 321()(3)(A).
9621 U.S.C. x 321(g).
9721 U.S.C. x 321()
9821 U.S.C. x 321(g)(1)(B).
9921 U.S.C. x 321(g)(1)(C). This provision will be discussed in detail in Part IV of this
paper.
37(1)
the dietary supplement contains only dietary ingredients, which have been
present in the food supply as an article used for food in a form in which the
food has not been chemically altered.
(2)
there is a history of use or other evidence of safety establishing that the
dietary ingredient when used correctly and according to the label will reasonably
be expected to be safe, and the manufacturer provides the FDA with studies or
articles showing the dietary ingredient will reasonably be expected to be safe.100
Once a manufacturer has the above information, it must be provided to
the FDA no more than 75 days prior to introduction. The FDA after 90 days
is instructed to put the non-condential information on public display.101 As
an alternative to the notication requirement, manufacturers can petition the
FDA setting forth the circumstances under which the new dietary ingredient
will be expected to be safe. The FDA then must evaluate the petition within 6
months.102
Dietary ingredients on the market before October 15, 1994 are not covered by
the new dietary ingredient requirements. They are instead \grandfathered."103If
the manufacturer fails to provide the FDA with the information necessary to
10021 U.S.C. x 350b(a).
101Id.
10221 U.S.C. x 350b(b).
103Bass at 40.
38show a reasonable expectation of safety for the new dietary ingredient, the di-
etary supplement will be deemed adulterated. Adulteration in the context of a
new dietary ingredient means that \there is inadequate information to provide
reasonable assurance that such ingredient does not present a signicant or un-
reasonable risk of illness or injury."104 The FDA bears the burden of proof on
this issue. Therefore, the dietary ingredient will be considered adulterated only
if the FDA proves the following:105

it is \new";

there is \inadequate information";

to provide \reasonable assurance";

that \such ingredient does not present a signicant or unreasonable risk of
illness or injury."
C. The Safety of Dietary Supplements under the DSHEA
10421 U.S.C. x 342(f)(1)(B).
105Bass at 41-42,
39Since the DSHEA removed dietary supplements from the denition of food ad-
ditives, the DSHEA strengthened the existing food adulteration provisions. Ba-
sically under the new DSHEA provisions, a dietary supplement will be deemed
to be an adulterated food if it \presents a signicant or unreasonable risk of ill-
ness or injury under (1) conditions of use recommended or suggested in labeling
or (2) if not conditions of use are suggested or recommended in the labeling,
under ordinary conditions of use."106 Under this provision, if a consumer uses
a dietary supplement in extreme doses or under extraordinary conditions, the
use will not be covered under the adulteration provision.107
Additionally, a dietary supplement will be deemed adulterated if it contains an
ingredient that the Secretary nds poses \an imminent hazard to public health
or safety."108 Finally, the new adulteration provisions for dietary supplements
encompass the \may be injurious" or \ordinarily injurious" standards set forth
in an earlier food adulteration provision109 \under the conditions of use rec-
ommended or suggested in the labeling of such dietary supplement."110 The
government bears the burden of proof on each element of adulteration.111
Finally, the DSHEA encompasses a good manufacturing practices provision.112
This provision is designed to ensure the proper treatment of dietary supplements
while they are being prepared, packed or held. The FDA has subsequently is-
sued an advance notice of proposed rulemaking to implement the DSHEA good
10621 U.S.C. x 342(f)(1)(A).
107Bass at 46.
10821 U.S.C. x 342(f)(1)(C).
10921 U.S.C. x 342(a)(1).
11021 U.S.C. x 321(f)(1)(D).
11121 U.S.C. x 342(f)(1).
11221 U.S.C. x 342(g)(1).
40manufacturing practices.113
D. Health Claims and Structure/Function Claims under the DSHEA
There are roughly three kinds of claims that a dietary supplement manufacturer
can make: drug claims, health claims, and structure/function claims. This pro-
vision addresses all three types of claims and was the provision that was most
lobbied and most feverishly debated. It remains one of the most controversial
provisions today.114
While classic drug claims are not allowed on the labeling, the new provisions
provide a safe harbor for structure/function claims that comply with substan-
tiation, labeling, and notication procedures:
For purposes of paragraph (r)(1)(B), a statement for a dietary supplement
may be made if{
(A) the statement claims a benet related to a classical nutrient deciency
disease and discloses the prevalence of such disease in the United States, de-
scribes the role of a nutrient or dietary ingredient intended to aect the struc-
ture or function in humans, characterizes the documented mechanism by which
a nutrient or dietary ingredient acts to maintain such structure or function, or
describes general well-being from consumption of a nutrient or dietary ingredi-
ent,
(B) the manufacturer of the dietary supplement has substantiation that such
statement is truthful and not misleading, and
(C) the statement contains, prominently displayed and in boldface type,
the following: This statement has not been evaluated by the Food and Drug
Administration. This product is not intended to diagnose, treat, cure, or prevent
any disease."
A statement under this subparagraph may not claim to diagnose, mitigate,
treat, cure, or prevent a specic disease or class of diseases. If the manu-
facturer of a dietary supplement proposes to make a statement described in the
rst sentence of this subparagraph in the labeling of the dietary supplement,
the manufacturer shall notify the Secretary no later than 30 days after the rst
marketing of the dietary supplement with such statement that such a statement
is being made.115
113See 62 Fed. Reg. 5700 (February 6, 1997).
114Id. at 55.
11521 U.S.C. x 343(r)(6) (emphasis added).
41Therefore, under the DSHEA, a manufacturer can make \structure/function"
claims as long as he complies with the substantiation, labeling and notica-
tion procedures of this section. This provision is best understood, however,
in light of the previous rules allowing manufacturers to make certain kinds of
structure/function claims for \foods". The FDCA drug denition permitted
foods to be labeled with claims that involved the nutrient's aect on the struc-
ture/function of the body.116 Traditional nutritional function claims such as
\calcium builds strong bones" were permitted before the DSHEA. Under the
DSHEA, however, dietary supplements are not deemed to be \food" for pur-
poses of the food exemption in the drug denition.117 Section 403(r)(6) of the
DSHEA thus arms that structure/function claims are acceptable for dietary
supplements, as long certain conditions are met.
Under the NLEA amendment to the FDCA, \health claims" relating a nu-
trient to a disease or health condition were allowed if they were authorized by
FDA regulation.118 The DSHEA creates an exemption to the NLEA provision
by allowing certain statements of nutritional support that meet the relevant
criteria (substantiation, labeling, and notication) to be made without a health
116This section denes drugs as \articles (other than food) intended to aect the structure
or any function of the body of man or other animals." 21 U.S.C. x 321(g)(1)(C). The dietary
supplement industry interpreted this section to mean that structure/function claims could
be made for foods. Bass at 15. The FDA maintained, however, that \food" did not include
dietary supplements other that those vitamins and minerals with recognized nutritional value.
Thus, a structure/function claim for any herb, amino acid, etc., was deemed an unapproved
drug claim by the FDA. See, e.g., 58 Fed. Reg. at 33,697-99.
11721 U.S.C. x 321 ().
11821 U.S.C. x 343(r)(1)(B).
42claim regulation promulgated by the FDA.119 The exact meaning of this section
of the DSHEA and the interpretation of the labeling and notication procedures
for structure/function claims have been frequently debated among practitioners
and academics.120 However, it is pretty clear that under the DSHEA that:

dietary supplements cannot claim to diagnose, treat, or cure a disease;

claims describing \general well-being from consumption of a nutrient or di-
etary ingredient" are allowed if the manufacturer follows the substantiation,
notication, and labeling procedures of the DSHEA; and,

supplements claiming an impact on the structure or function of the body are
allowed if the manufacturer follows the substantiation, notication, and labeling
procedures of the DSHEA.121
119Bass at 56.
120Bass and Young state that traditional dietary ingredient structure/function claims can
still be made by manufacturers of dietary supplements without meeting the DSHEA require-
ments. However, where the claim is not a classic nutritional function claim, the DSHEA
requirements of notication and labeling apply. Id. at 56. See also McNamara, Stephen H.
\Structure/Function Claims in Dietary Supplement Labeling: Not All of These Claims Need
to Be Submitted to FDA and Accompanied in Labeling by the DSHEA Disclaimer." 54 Food
and Drug L.J. 35, 36 (1999) (arguing that the \eect of the opening phrase of section 403(r)(6)
is to provide that, in the case of a dietary supplement, a statement that is a health claim may
be made in labeling without the usual requirements for health claims, if instead the statement
complies with provisions of the section, including use of the disclaimer and notication to
FDA. Under the plain language of sections 403(r)(1)(B) and 403(r)(6), however, there is no
need for a structure/function claim to comply with section 403(r)(6) requirements unless the
claim [is a health claim]."
12121 U.S.C. x 343(r)(6).
43E. The DSHEA's Dietary Supplement Labeling Requirements
Under the labeling guidelines set forth in the NLEA, a dietary supplement must
be labeled in an appropriate manner and meet the following criteria:122
(i) nutrition information shall rst list those dietary ingredients that are
present in the product in a signicant amount and for which a recommenda-
tion for daily consumption has been established by the Secretary, except that a
dietary ingredient shall not be required to be listed if it is not present in a signif-
icant amount, and shall list any other dietary ingredient present and identied
as having no such recommendation;
(ii) the listing of dietary ingredients shall include the quantity of each such
ingredient (or of a proprietary blend of such ingredients) per serving;
(iii) the listing of dietary ingredients may include the source of a dietary
ingredient; and
(iv) the nutrition information shall immediately precede the ingredient in-
formation required under subclause (i), except that no ingredient identied pur-
suant to subclause (i) shall be required to be identied a second time.
Congress instructed the FDA to issue regulations that are \appropriate to
the product," but left open the specic format of the nutrition information
panel.123
Under the DSHEA, the labeling of a supplement must state that it is a
\dietary supplement."124 Dietary supplements now must also list the name of
each dietary ingredient and the quantity of each dietary ingredient.125 If the
ingredient is an herb or botanical product, the label must list the part of the
plant from which it was derived.126
F. The DSHEA's Exception to the Denition of \Labeling" { Third Party Literature
This section of the DSHEA changes the state of the law established by the Ko-
12221 U.S.C. 343(q)(5)(F).
123Id.
12421 U.S.C. 343(s)(2)(B)
12521 U.S.C. 343(s)(2)(A)(ii)(I).
12621 U.S.C. 343(s)(2)(C).
44rdel and Urbuteit cases addressing the denition of \accompanying labeling."127
The DSHEA states that:
A publication, including an article, a chapter in a book, or an ocial ab-
stract of a peer-reviewed scientic publication that appears in an article and
was prepared by the author or the editors of the publication, which is reprinted
in its entirety, shall not be dened as labeling when used in connection with the
sale of a dietary supplement to consumers when it{
(1) is not false or misleading;
(2) does not promote a particular manufacturer or brand of a dietary
supplement;
(3) is displayed or presented, or is displayed or presented with other such
items on the same subject matter, so as to present a balanced view of the
available scientic information on a dietary supplement;
(4) if displayed in an establishment, is physically separate from the dietary
supplements; and
(5) does not have appended to it any information by sticker or any other method.
(b) Application
Subsection (a) of this section shall not apply to or restrict a retailer or
wholesaler of dietary supplements in any way whatsoever in the sale of books
or other publications as a part of the business of such retailer or wholesaler.
(c) Burden of proof
In any proceeding brought under subsection (a) of this section, the burden
of proof shall be on the United States to establish that an article or other such
matter is false or misleading.128
This section allows manufacturers and distributors to send sales publications
to retailers as long as they meet the criteria set out in the section.129 This sec-
tion was put into the statute in response to a public outcry against existing
FDA policies deemed to be \censorship."130The DSHEA puts no restrictions
on who may author a publication, as long as it meets the ve criteria in the
statute (i.e., is not false or misleading, does not promote a particular brand, is
balanced, is physically separate, and is not stickered with information.)131
127See supra notes 5 and 7.
12821 U.S.C. x 343-2.
129Bass at 51.
130Id.
131Id.
45G. The DSHEA's Establishment of the Oce of Dietary Supplements
The DSHEA establishes both a Commission on Dietary Supplement Labels
and an Oce of Dietary Supplements within the National Institutes of Health.
Specically, the Commission on Dietary Supplement Labels|a seven-member
Commission appointed by the President|was established to conduct a study on
the regulation of dietary supplement label claims.132 The Commission is given
the power to hold hearings, take testimony, receive evidence, and obtain nec-
essary information directly from any federal agency or department to evaluate
how to provide truthful and non-misleading information about dietary supple-
ments to consumers.133 The members of the Commission should have \expertise
and experience in dietary supplements and in the manufacture, regulation, dis-
tribution and use of such supplements."134 The DSHEA further requires that
three or more members of the Commission be \qualied by scientic training
and experience to evaluate the benets to health of the use of dietary supple-
ments" and at least one of the three to have \experience in pharmacognosy,
medical botany, traditional herbal medicine, or other related sciences."135 The
Senate Report goes on to state that the Commission should look into the issue
of whether the FDA is the most appropriate governmental body to make nal
decisions regarding health claims.136
Additionally, the Commission was charged with making recommendations about
13221 U.S.C. x 343 note, x 12(b).
13321 U.S.C. x 343 note, x 12(d).
13421 U.S.C. x 343 note, x 12(b).
13521 U.S.C. x 343 note, x 12(b)(2).
136S. Rep. No. 410, 103d Cong., 2d Sess. 30 (1994).
46the \use of literature in connection with the sale of dietary supplements."137
The members of the Commission were appointed in late 1995 and were given
the task of submitting a nal report on the study by October 1996.
The DSHEA also requires the establishment of an Oce of Dietary Supple-
ments.138 The purpose of the oce is to \explore more fully the potential role
of dietary supplements as a signicant part of the eorts of the United States to
improve health care" and to \promote scientic study of the benets of dietary
supplements."139 The Senate Report accompanying the statute states that the
major function of the oce would be to provide advocacy and scientic infor-
mation regarding the benets of dietary supplements.140 Thus, this oce was
not intended to have regulatory authority over dietary supplements.141
13721 U.S.C. x 343 note, x 12(c).
13842 U.S.C. x 287c-11(b).
13942 U.S.C. x 287c-11(b).
140S.Rep.No. 103-410.
141Id.
47Part IV { Post-DSHEA Regulation of Dietary Supplement Structure/Function
and Health Claims
As previously discussed, the DSHEA permits dietary supplement manufactur-
ers to make so-called structure/function claims under certain conditions without
pre-clearance. Moreover, since dietary supplements are regulated as foods un-
der the DSHEA, the use of pre-approved health claims on labeling became an
issue for dietary supplement manufacturers and the FDA. These issues have
generated the most interest and controversy in the legislative, judicial, and reg-
ulatory arena and are at the heart of the statute's intent|to increase consumer
access to quality information about dietary supplements. This section explores
the controversy and current state of law with respect to structure/function and
health claims.
A. Health Claims
Congress passed the NLEA to prohibit unfounded and/or inaccurate health
claims that have the potential to defraud consumers while at the same time to
permit health claims based on scientically valid information.142 The NLEA
authorizes the dissemination of health claims where the FDA has found that
such claims are reliable. To determine reliability, Congress required the FDA
to promulgate rules. For foods, Congress required the FDA to use a \signi-
cant scientic agreement standard."143 Because the DSHEA requires the FDA
to regulate dietary supplements as foods, the health claim procedure then also
applied to dietary supplements.
142Vladeck, David C. \Devaluing the Truth: Unveried Health Claims in the Aftermath of
Pearson v. Shalala." 54 Food and Drug L.J. 535 (1999).
14321 U.S.C. x 343(r)(3)(B).
48The FDA denes a health claim as \any claim... that expressly or by impli-
cation... characterizes the relationship of any substance to a disease or health-
related condition."144 Congress gave the FDA the task to determine the stan-
dard for dietary supplements, and the FDA decided that the procedures used
for health claims in food should also apply to health claims for dietary supple-
ments.145 Thus, the FDA permits a health claim for dietary supplements only
where \signicant scientic agreement" supports the claim. The FDA must pre-
authorize the health claim. As of 1999, the FDA had approved only a handful
of health claims for use by dietary supplements.146
The Food and Drug Administration Modernization Act of 1997 (FDAMA)
changed the landscape of regulation of health claims somewhat. The FDAMA
added a new procedure for using health claims in labeling.147 Specically, the
FDAMA allows for a health claim based on \an authoritative statement of a
scientic body of the United States Government with ocial responsibility for
public health protection or research directly relating to human nutrition... \148
In order to use the health claims on the label, the manufacturer must submit
to the FDA, at least 120 days before the introduction of the supplement into
interstate commerce: (1) a notice of the claim; (2) a copy of the authoritative
14421 C.F.R. x 101.14(a).
14521 C.F.R. xx 101.14, 101.70.
146Examples of approved health claims are (1) claims that described the relationship between
calcium and osteoporosis and (2) claims that described the relationship between folic intake
and neural tube defects.
147Pinco, Robert C. and Todd H. Halpern, \Guidelines for the Promotion of Dietary Sup-
plements: Examining Government Regulation Five Years After Enactment of the Dietary
Supplement Health and Education Act of 1994." 54 Food and Drug L.J. 567, 573. (1999).
14821 U.S.C. x 343(r)(3)(C)(i). This portion of the Act did not apply to health claims based
on authoritative statements for dietary supplements. See 64 Fed. Reg. 3250, 3251 (January
21, 1999). The FDA, however, has proposed to interpret the regulations the same way for
conventional foods and dietary supplements. See 64 Fed. Reg. at 3251-3252.
49statement relied on; and (3) a balanced representation of the scientic literature
relating to the health claim.149 The claim must be an accurate depiction of the
authoritative statement and may not be misbranded.150
The FDA, however, signicantly cut back on the strength of the FDAMA in its
subsequent regulations by limiting the denition of \authoritative statement"
and narrowly interpreting \signicant scientic agreement."151 In an interim
nal rule issued in response to various health claims presented to the FDA, the
FDA denied all petitions on various grounds.152 The FDA determined that
some of the statements were invalid because they were not conclusive enough
and further studies were required. Other studies were held invalid because they
did not conrm that the health claim was scientically valid or well-established.
Other authoritative statements were rejected because they were based on sci-
entic review by only one segment of the scientic body, rather than the entire
scientic body, or did not reect consensus of the entire scientic body.153 Even
more were denied because the evidence implied the studies were only prelimi-
nary rather than conclusive.154 Predictably, the narrow view taken by the FDA
with respect to health claims angered many, including Rep Dan Burton, who
argued the regulations were tantamount to censorship.155
Apparently, the courts are starting to agree with Rep. Burton's view on the
FDA's regulatory policy. In Nutritional Health Alliance v. Shalala, the Sec-
14921 U.S.C. x 343(r)(3)(C)(ii).
15021 U.S.C. x 343(r)(3)(C)(iii-iv).
151Pinco at 573.
15263 Fed. Reg. 34,084-34,112 (June 22, 1998).
153Id. at 34,093.
154Id.
155Letter from Rep. Dan Burton (R-IN) to Michael Friedman, Lead Deputy Commissioner,
Food and Drug Administration (August 13, 1998).
50ond Circuit held that the NLEA's requirement for prior approval of all health
claims|a requirement that could produce a prior restraint of 540 days|was
constitutionally acceptable.156 However, the leading court decision in the area of
health claims is Pearson v. Shalala, issued one year after Nutritional Health Alliance.157On
January 15, 1999, the Pearson Court held that the FDA's policy regarding eval-
uation of health claims was unconstitutional. The plaintis in the case were
dietary supplement marketers who wanted the FDA to authorize four health
claims in order to boost the \allure" of their dietary supplement labels. The
health claims were as follows:
(1) \
Consumption of antioxidant vitamins may reduce the risk of certain kinds
of cancer."
(2) \
Consumption of ber may reduce the risk of colorectal cancer."
(3) \
Consumption of omega-3 fatty acids may reduce the risk of coronary heart
disease."
(4) \
156144 F.3d 200 (2nd Cir. 1998).
157164 F.3d 650 (D.C. Cir. 1999).
51.8 mg. of folic acid in a dietary supplement is more eective in reducing the
risk of neural tub defects than a lower amount in foods in common form."158
The FDA denied all four health claims because, in their view, all four claims
failed to demonstrate \signicant scientic agreement."159 The D.C. Circuit
found that the FDA's policy was an unconstitutional restriction on free speech.
Specically, the Court found that the FDA was required to consider whether
inclusion of some appropriate disclaimers with the health claim would negate the
potentially misleading nature of the health claims.160 Additionally, the Court
found that the \signicant scientic agreement" standard was too vague and
ordered the FDA to dene the phrase and consider the adequacy of the claims
in the context of the proposed disclaimers.161 The D.C. Circuit also held that
the Administrative Procedure Act requires the FDA to explain why it rejected
the four health claims. To do so, the Court reasoned, the FDA must give some
denitional content to \signicant scientic agreement."162
The aftermath of Pearson is not yet entirely determined. The FDA has issued
a notice requesting scientic information related to the four health claims in
the case.163 The FDA will use the data to evaluate the Pearson health claims
pursuant to the directives of the D.C. Circuit. Even more recently, the FDA has
issued an announcement of a public meeting to solicit comments regarding the
158Id. at 652.
159Id. at 653.
160Id. at 658.
161Id. at 661.
162Id. at 660.
16364 Fed. Reg. 48,841 (Sept. 8, 1999).
52implementation of the Pearson decision.164 Specically, the meeting will discuss
whether claims about an eect on an existing disease may be made as health
claims, or whether they should be regulated as drug claims. The meeting will
also address the disclaimer issue raised in Pearson, namely whether a disclaimer
placed on the label qualifying the health claim would render the statement non-
misleading.
While the proponents of Pearson think they have won a battle for more consumer
choice, others argue that the Pearson decision will actually harm consumers. For
example, manufacturers may now try to forgo the new drug approval process
and market what seemingly are new drugs as dietary supplements.165 This is
because after Pearson, it is possible that dietary supplements may make the
same claims as drugs but do not have to go through the new drug approval
process.166 It would thus by irrational for a manufacturer to go through the
new drug approval process when it could put its product on the market as a
supplement and make disease prevention claims.167
B. Structure/Function Claims
As previously noted, the DSHEA explicitly authorizes dietary supplement la-
beling to contain statements of nutritional support or structure/function state-
ments as long as the following criteria are met:
16465 Fed. Reg. 14219 (March 16, 2000).
165Vladeck at 552.
166Id.
167Id. at 552-553.
53(1)
the manufacturer of the dietary supplement has substantiation at the time
the claim is made that the statement is truthful and non-misleading to the con-
sumer168
(2)
the labeling contains the mandatory disclaimer \this statement has not been
evaluated by the food and drug administration. This product is not intended
to diagnose, treat, cure, or prevent any disease" prominently displayed in bold-
faced type169
(3)
the manufacturer of dietary supplement must notify the FDA of the struc-
ture/function claim within 30 days after the marketing of the dietary supple-
ment.170
If the FDA after receiving notice disapproves of a claim, it will issue a cour-
tesy letter, but the letter has no legally binding eect.171 The letter merely
puts the manufacturer on notice that the claim may lead to future regulatory
action.
Under the terms of the DSHEA, a structure/function claim cannot claim to di-
16821 U.S.C. x 343(r)(6)(B).
16921 U.S.C. x 343(r)(6)(C).
17021 U.S.C. x 343(r)(6).
171Pinco at 576.
54agnose, treat, cure or prevent a disease.172 On April 29, 1998, the FDA issued
a proposed rule attempting to dene the parameters of a structure/function
claim.173Therefore, the denition of \disease" became very important in dis-
tinguishing disease claims that are not allowed for dietary supplements from
structure/function claims that are allowed. The rule proposed to broaden the
denition of \disease" to include:
any deviation from, impairment of, or interpretation of the normal structure
or function of any part, organ or system (or combination thereof) of the body
that is manifested by a characteristic set of one or more signs or symptoms. For
purposes of this denition, \signs or symptoms" include laboratory or clinical
measurements that are characteristic of a disease, such as elevated cholesterol
fraction, uric acid, blood sugar and glycosylated hemoglobin, and characteristic
signs of disease, such as elevated blood pressure or intraocular pressure.174
The comments to the FDA's denition of disease and related regulatory
stances were based primarily in a notion that Congress did not intend the FDA
to use such a broad denition of disease.175 Specically, FDA opponents argued
that Congress must have been aware of the prior denition of disease when it
enacted the DSHEA and therefore intended the FDA to use the older, narrower
denition. Additionally, they argued that FDA's denition was so broad that
it would sweep in many minor abnormalities that would not ordinarily be con-
sidered a disease.176 If the FDA can stretch the denition of disease broadly
enough, the broad denition will eectively eliminate the structure/function
17221 U.S.C. x 343(r)(6).
17363 Fed. Reg. 23624.
17464 Fed. Reg. 36,824, 36825. (denition contained in FDA's response to comments
generated by April 29, 1998 proposed rulemaking).
175Id. at 36,825.
176Id.
55claims that Congress intended to be allowable under the DSHEA.
In addition to broadening the denition of disease, the regulations also stated
that natural states such as aging, menopause, pregnancy, and the menstrual cy-
cle were not themselves diseases, but \could be associated with abnormal condi-
tions that were diseases."177 Therefore, the FDA proposed to treat statements
that a dietary supplement has an eect on a condition associated with a natural
state as a disease claim if the condition presented symptoms of an abnormal-
ity.178 The FDA presented the following as examples of abnormal conditions:
hot ashes, decreased sexual function associated with aging, and premenstrual
syndrome. Many comments on this issue suggested that some of the examples
were so common that they could not be considered an abnormality nor a dis-
ease.179
Moreover, the FDA proposed to treat express and implied disease claims as
disease claims requiring prior approval by the FDA. FDA's reason for treating
implied disease claims like express claims was that it did not want a savvy man-
ufacturer to craft an implied disease claims in a manner that will be understood
by consumers as an express disease claim. It gave the following example:

Express claim { \for the treatment of lung cancer"
177Id.
178Id.
179Id.
56
Implied claim { \shrinks tumors of the lung"180
Opponents to the FDA stance on implied disease claims argued that Congress
intended to permit implied disease claims in the DSHEA and the FDA stance
was therefore contrary to congressional intent.181
The massive public outcry caused the FDA to reevaluate its position with
respect to the regulation of structure/function claims, and led eventually to
a nal rule issued in January of 2000.182 The nal regulations soften the
FDA's stance somewhat toward the regulation of dietary supplement struc-
ture/function claims. The nal regulations made the following changes:183
(1)
proposed broader denition of \disease" was deleted;
(2)
FDA will use the preexisting denition of \disease or health-related condi-
tion" found in 21 C.F.R. x 101.14(a)(5). This is the denition put forth as part
of the implementation of the NLEA.
(3)
express disease claims such as \prevents osteoporosis" are precluded are not
180Id. at 36,826.
181Id. at 36,825-36,826.
18265 Fed. Reg. 1000 (January 6, 2000).
183Id. at 1000.
57considered to be permissible structure/function claims;
(4)
implied disease claims such as \prevents bone fragility in post-menopausal
women" are not considered to be permissible structure/function claims;
(5)
claries that disease claims (express and implied) can be made through the
name of a product, a statement about the formulation of a product, or through
the use of pictures or symbols;
(6)
claries that health maintenance claims and non-disease claims are permis-
sible claims under this rule;
(7)
certain conditions that are associated with natural states or processes that
do not cause signicant or permanent harm will NOT be treated as diseases {
ex. hot ashes, common symptoms associated with the menstrual cycle, mild
memory loss and hair loss associated with aging, and noncystic acne; and,
(8)
uncommon or serious conditions associated with natural states or processes
58WILL be treated as diseases { ex. toxemia of pregnancy, senile dementia, severe
depression associated with the menstrual cycle, and cystic acne.
The FDA has softened its position in terms of the denition of disease by
reverting to the prior, narrower denition of disease. Also, the FDA has decided
to include statements made about common conditions associated with life's
natural processes as long as the condition is not signicant. Consequently, the
FDA did compromise its earlier position somewhat in response to the public
outcry. There have been no signicant developments since the nal regulation
was put into place. However, the FDA has announced a meeting to discuss
safety issues associated with dietary supplement use during pregnancy.184 This
meeting was announced in response to health professionals and other individuals
concerned about safety after the enactment of the January nal rules. At any
rate, while these new regulations are only a few months old, they seem to
indicate that the FDA will be more willing to allow manufacturers to make
certain structure/function claims without pre-approval.
18465 Fed. Reg. 9230 (February 24, 2000).
59Part V { Post-DSHEA Changes in the Denition of \Dietary Supplements"
As previously discussed, the denition of \dietary supplements" established by
the DSHEA is very broad. It includes vitamins, minerals, herbs, amino acids,
and others. It also includes articles approved as a new drug, as long as the
article was previously marketed as a dietary supplement or food.185
Under the DSHEA, an article is not a dietary supplement if it is an article
that is approved as a new drug, a certied antibiotic, or a licensed biologic, as-
suming they were not previously marketed as a food or dietary supplement.186
Additionally, articles authorized for investigation as a new drug, antibiotic or
biological for which substantial investigations have been instituted and made
public are also not included in the denition of \dietary supplement," assuming
they weren't previously marketed as a food or a dietary supplement.187
The exact meaning of the exclusionary and inclusionary denitional provisions
were tested in Pharmanex v. Shalala.188 Pharmanex marketed Cholestin as a
dietary supplement. Cholestin was composed solely of milled red yeast rice.
Cholestin was intended for use in helping to maintain a health cholesterol level.
The red yeast rice in Cholestin was a natural source of mevinolin, which is
chemically indistinguishable from lovastatin. Lovastatin is the active ingredient
in the prescription drug Mevacor, approved as a new drug in 1987. Therefore,
a natural ingredient found in Cholestin was also an active ingredient in a pre-
scription drug.
18521 U.S.C. x 321()(3)(A).
18621 U.S.C. x 321()(3)(B)(i).
187Id.
18835 F.Supp.2d 1341 (D.Utah 1999)
60The FDA advised Pharmanex that it considered Cholestin to be a drug that
required pre-approval by the FDA for marketing. FDA subsequently barred
Pharmanex from importing red yeast rice, and Pharmanex in turn brought an
action for preliminary injunction and declaratory judgment against the FDA.
The District Court in Utah examined whether Cholestin was subject to the
clause in the DSHEA, which excludes \an article that is approved as a new
drug" from the denition of \dietary supplement."189 FDA maintained the
position that lovastatin itself was an \article" approved as a new drug. The
District Court, however, determined that \article" refers to the nished drug
product, not a component of the product.190
This decision could signicantly limit FDA's ability to regulate dietary sup-
plements and has been met with some controversy. One argument is that
the \decision essentially eviscerates the exclusionary component of the dietary
supplement denition, which was enacted to protect pioneer pharmaceuticals
approved via the NDA process from direct competition from the same active
ingredient by makers of dietary supplements. Under the District Court's inter-
pretation, any slight variant... would circumvent the exclusion."191 Moreover,
this decision could encourage \unscrupulous dietary supplement manufacturers"
to \nd either variants or `phyto' alternatives to major pharmaceutical prod-
ucts."192 Along the same lines, others have noted that the \decision encourages
manufacturers of dietary supplements to nd and market `natural' substances,
18921 U.S.C. x 321()(3)(B).
19035 F.Supp.2d at 1348.
191Pinco at 571.
192Id.
61which are the active ingredients in prescription drugs, without going through the
[new drug approval] process otherwise required."193 Additionally, prescription
drug manufacturers may be discouraged from going through clinical trials and
medical studies for fear that a dietary supplement manufacturer could market
the same product at a lower cost and with less regulation.194
As the Pharmanex decision winds through the appeals process, many argue that
the decision could be problematic from a consumer safety standpoint. Lovas-
tatin, the substance at issue in the Pharmanex case, can cause liver dysfunction
and should not be used on women who are likely to conceive.195 Additionally, it
is recommended that physicians monitor patients taking lovastatin for possible
drug interactions. Since many consumers taking the herbal medicine will not
inform their physicians and will assume it is safe, this could be a problem from
a consumer safety standpoint.196
193Khatcheressian at 634.
194Id.
195Id. at 635.
196Id.
62Part VI { Safety and Burden of Proof Issues after the DSHEA
Since the DSHEA declares that dietary supplements are not to be regu-
lated generally as food additives or drugs, manufacturers are not required to go
through a pre-market approval process. Consequently, the DSHEA eectively
shifts the burden of proof on safety from the dietary supplement manufacturer
to the FDA. Therefore, if the FDA has a safety concern about a dietary sup-
plement, it must armatively prove that the product will be harmful before it
can remove the product from shelves.197
Specically, the dietary supplement adulteration portion of the Act states that
\in any proceeding under this subparagraph, the United States shall bear the
burden of proof on each element to show that a dietary supplement is adul-
terated. The court shall decide any issues under this paragraph on a de novo
basis."198 One commentator has interpreted this provision to mean the FDA
should issue guidelines instead of the traditional regulations in the context of
dietary supplement adulteration:
Because of certain unique provisions of the DSHEA|provisions that were
specically considered during the enactment of DSHEA and that do not appear
in other sections of the FDCA|any regulations that FDA issues to interpret
or enforce the adulteration provisions of sections 402(a)(1) and (f)(1) of the
FDCA with respect to dietary supplements cannot have the force and eect
of law or be eligible for direct enforcement in court, and would have no more
status than FDA's nonbinding guidelines. Accordingly, it appears that instead
of issuing regulations, FDA should issue guidelines with respect to any agency-
desired criteria for dietary supplements under sections 402(a)(1) and (f)(1) of
the FDCA.199
197Khatcheressian at 628.
19821 U.S.C. x 342(f)(1).
199McNamara, Stephen H., A. Wes Singer, and Evan P. Phelps. \DSHEA Provisions Conne
FDA's Authority to Issue Regulations that Concern Allegedly Adulterated Dietary Supple-
63Even if the adulteration provision does not constrain FDA's power to issue
regulations in the way specied above, it is clear that at the very least that the
DSHEA makes it more dicult for the FDA to nd that a dietary supplement
is adulterated. Since there is no longer any pre-market approval mechanism
for dietary supplements under the DSHEA, the FDA will be ghting an up-hill
battle in its attempts to keep unsafe dietary supplements o the market.
ments." 54 Food and Drug L.J. 595, 597. (1999). (emphasis added).
64Part VII { Post-DSHEA Labeling Requirements/Third Party Literature Requirements
A. The Dietary Supplement Label
The DSHEA mandates that dietary supplements bear nutrition labeling \in a
manner which is appropriate" for the product.200 Congress left it up to the
FDA to determine what this would be. The FDA published proposed regu-
lations regarding the labeling of dietary supplements on December 28, 1995201
and issued nal regulations on September 23, 1997.202 Eective March 23, 1997,
the nal rules require dietary supplements to be labeled as such and to carry a
\Supplement Facts" panel on the label (similar to the Nutrition Facts panel for
foods). Specically, the Supplements Facts panel will show:

the manufacturer's suggested serving size;

information on nutrients present in signicant level, including the percent
Daily Value of the those nutrients; and,

all other dietary ingredients present in the product.203
Additionally, the nal rule requires that products that contain botanical
20021 U.S.C. x 343(q)(5)(F).
20160 Fed. Reg. 67,197
20262 Fed. Reg. 49,883.
203Id.
65ingredients be labeled with the common or usual name along with the part of
the plant (such as root, stem, or leaf) used to make the products.204 Finally,
when the terms \high potency" and \antioxidant" are used on the label, the
FDA has provided additional, specic guidance to manufacturers as to when
these terms are acceptable for use on the dietary supplement label205
B. The Third Party Literature Exception
The \Third Party Literature" exception in the DSHEA allows third parties
(presumably persons or entities other than the manufacturers or distributors of
dietary supplements) to distribute certain publications to consumers in connec-
tion with the sale of particular dietary supplements.206 In order to qualify for
the exemption, however, the literature must not be false or misleading, must
not promote a particular manufacturer or brand of dietary supplement, must
present a balanced view of the available scientic information on the supple-
ment, must be physically separate from the dietary supplement, and must not
be stickered with information.207
There are many available contestable issues within the statute, but the FDA
has been relatively cautious in contesting independent status of particular pub-
lishers so far.208 A manufacturer appears to be free to commission a third party
to publish information about a dietary supplement, as long as the manufacturer
204Id.
205Id.
20621 U.S.C. x 343-2.
207Id.
208Raubicheck, Charles J. \DSHEA's Third-Party Literature Exemption: Mail Order Sales,
Direct Marketing, and Internet Use." 54 Food and Drug L.J. 587, 589. (1999).
66does not exercise any control over the content.209 Recently, the FDA issued a
warning letter to a manufacturer who issued cookbooks as third-party literature
because the cookbooks were authored by the company's managerial employees
who also had responsibility for marketing and labeling the company's dietary
supplement.210 It would appear that \permissible channels of dissemination in-
clude mail order, direct marketing, and Internet sales and promotion, in addition
to sales and promotion in the traditional retail store context."211
As Internet use grows in popularity in the U.S., Internet sales and mar-
keting in connection with the third-party literature exception will become very
important. The FDA has determined in many instances that dietary supple-
ment claims on the Internet are labeling.212 Therefore, in order to t within
the third-party literature exception, Internet claims should be used on a web-
site where dietary supplements are actually being sold to comply with the \in
connection with the sale" requirement in the DSHEA.213 Likewise, the require-
ment of \physical separation" could be met through hyperlinks. The hyperlinks
should take the user rst to generic pages that describe the type of supple-
ments involved and then take the user to the third party literature page. This
could prevent the information from being construed as endorsing a particular
brand.214 The Internet sale of dietary supplements is a relatively new issue, but
209Id.
210Letter from Joseph R. Baca, Director of the Dallas District Oce, Food and Drug Ad-
ministration, to The Stevita Company (April 9, 1999).
211Raubicheck at 593.
212Id. at 592.
213Id.
214Id.
67the FDA will no doubt have to address this issue further in the near future.
68Part VIII { Current Bills in Congress { The Future of DSHEA Regulation?
While the FDA was developing its regulatory stance on dietary supplements in
response to the DSHEA, FDAMA, and related acts, Congress was also carving
out new policy. During the 106th Congress, several pertinent bills were proposed
to change the regulatory status of dietary supplements even more.
Rep. Ron Paul introduced the Consumer Health Free Speech Act215 in the
House in March of 1999. As introduced, the purpose of the bill is to change the
food adulteration standards for dietary supplements. H.R. 1077 deems a dietary
supplement adulterated if it (2) presents a signicant AND unreasonable risk
of illness or injury under ordinary or label-suggested use or (2) is a new dietary
ingredient for which there is inadequate information to provide reasonable as-
surance that the ingredient does not present a signicant AND unreasonable
risk of illness. The current food adulteration provision uses a signicant or
unreasonable standard.216 The bill was referred to the House Committee on
Commerce. There has been no further action on the bill since the committee
referral.
Sen. Michael D. Crapo proposed a bill entitled Dietary Supplement Fairness in
Labeling and Advertising Act217 in October of 1999. The bill was designed to
nullify the proposed regulations issued by the FDA on structure/function claims
in April of 1998.218 Additionally, the bill substantially relaxed advertising re-
quirements for dietary supplements to include the claims made on the labels of
215H.R. 1077. 106th Cong., 1st Sess., (1999).
216See 21 U.S.C. x 342(f)(1)(A).
217S. 1749, 106th Cong., 1st Sess., (1999).
21863 Fed. Reg. 23624.
69the supplements, so that Americans will gain more access to information about
dietary supplements. The bill was sent to the Senate Health, Education, Labor,
and Pensions committee on October 19, 1999. This was the last action on S.
1749.
Rep. Frank Pallone, Jr. proposed the Nutraceutical Research and Education
Act219 on October 1, 1999. The purpose of the Act was to establish and promote
clinical research and development on the health benets of dietary supplements.
Additionally, the bill creates a new legal classication for dietary supplements
and food with health benets. The bill was referred to the House Committee
on Commerce, Subcommittee on Health and the Environment and to the House
Committee on the Judiciary.
Finally, Rep. Dan Burton, a big proponent of the health benets of dietary sup-
plements and consumer access to dietary supplements, proposed H.R. 3306220
in November 1999 to provide that money spent on dietary supplements should
be treated as medical expenses for purposes of the Internal Revenue Code. The
Bill was referred to the House Committee on Ways and Means.
219H.R. 3001, 106th Cong., 1st Sess. (1999).
220H.R. 3306, 106th Cong., 1st Sess. (1999).
70Conclusion
The regulation of dietary supplements has been a very contentious issue
since its inception. Meanwhile, the number of dietary supplements on the mar-
ket seems to be proliferating. A consumer is now able to nd an assortment
of dietary supplements for any one ailment, ranging from dietary supplements
used to improve one's cholesterol to supplements used to improve one's mood.
Advertising for dietary supplements has increased, and consumers now seem
more willing to turn to dietary supplements, particularly some herbal supple-
ments, before they obtain prescription medication for their specic problem.
One could argue that this development is good. Consumers are now able to
take control of their health care and make informed choices, given the informa-
tion contained in dietary supplement labels after the enactment of the DSHEA.
The DSHEA changed FDA's paternalistic attitude and forced the agency to
realize the potential health benets of dietary supplements.
The FDA, however, has long been concerned with the safety of these dietary
supplements. Lately, there have been a number of high-prole incidents involv-
ing people being injured from using dietary supplements to supposedly improve
their health. Thus, the conict will continue as long as the FDA continues to
maintain a consumer safety position and the industry and others maintain a
consumer choice position.
The federal regulation of dietary supplements will remain an interesting and
71dynamic issue that is marked by controversy. The future of dietary supplement
regulation will be a continuation of the struggle to balance consumer protection
against the necessity for consumer access to useful and non-misleading infor-
mation about the role of dietary supplements in one's diet and health. With
any luck, the ongoing battle on the part of the FDA, Congress, the courts, and
industry to develop a regulatory scheme will result in a sensible and eective
policy for the consumer.
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